Main content

    Gastroenterology/Interventional Endoscopy Clinical Trials

    Gastroenterology Services
    Interventional Endoscopy Services

    Adult Clinical Trials Main Page

    Gastric Motility-Adults  |  Interventional Endoscopy  |  Pancreatic Cancer

    Gastric Motility-Adults

    Principal Investigator/Contact Information Protocol Title Patient Population Recruitment Period
    Principal Investigator:
    William Snape, MD

    Contact:
    Mary Green
    415-600-1367
    Email greenem@cpmcri.org    		 Gastroparesis Registry: Observational study to establish a registry of patients with gastroparesis to determine epidemiology, etiology, and degree of morbidity
    Visit the Gastroparesis study on ClinicalTrials.gov.    		 Subjects at least 18 years of age with confirmed delayed gastric emptying or symptomatic nausea and vomiting due to diabetes or of idiopathic nature
    Open
    Principal Investigator:
    William Snape, MD

    Contact:
    Mary Greene
    415-600-1367
    Email greenem@cpmcri.org     		HALO Patient Registry: Ablation of Barrett's Esophagus, A Multi-Center Patient Registry
    NCT00848237
    Visit the Barrett's esophagus or Intestinal metaplasia study on ClinicalTrials.gov.    		 Subjects with Barrett's esophagus or Intestinal Metaplasia
    Open
    Principal Investigator:
    William Snape, MD

    Contact:
    Mary Greene
    415-600-1367
    Email greenem@cpmcri.org     		Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG)
    Visit the Gastroparesis study on ClinicalTrials.gov.    		 Subjects aged 25 – 65 years old at registration in the Gastroparesis Registry Study with moderate to severe symptoms of idiopathic gastroparesis
    Coming Soon
    Principal Investigator:
    William Snape, MD

    Contact:
    Mary Greene
    415-600-1367
    Email greenem@cpmcri.org     		Pilot Study of the Safety, Feasibility, and Potential Efficacy of Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis (GLUMIT-DG)
    NCT01030341
    Visit the GLUMIT-DG study on ClinicalTrials.gov.    		 Subjects with Type 1 or Type 2 diabetes mellitus for at least 2 years
    Coming Soon

    Back to top

    Interventional Endoscopy

    Principal Investigator/Contact Information Protocol Title Patient Population Recruitment Period
    Principal Investigator:
    Kenneth Binmoeller, MD

    Contact:
    Nestor Mena
    415-600-1744
    Email menanz@cpmcri.org    		Endoscopic drainage of pancreatic pseudocyst using a novel prototype forward viewing ultrasonic endoscope. Subjects undergoing Endoscopic evaluation and drainage of a pancreatic cyst Open
    Principal Investigator:
    Kenneth Binmoeller, MD

    Contact:
    Nestor Mena
    415-600-1744
    Email menanz@cpmcri.org    		Evaluation of Clinical Outcomes in Interventional Endoscopy Services Subjects receiving treatment through Interventional Endoscopy Services Open
    Principal Investigator:
    Kenneth Binmoeller, MD

    Contact:
    Nestor Mena
    415-600-1744
    Email menanz@cpmcri.org    		Halo Patient Registry: Ablation Of Barrett’s Esophagus
    Visit the Barrett’s esophagus study on ClinicalTrials.gov.    		Subjects who have Barrett’s esophagus (a pre-cancerous change to the lining of the swallowing tube from acid reflux) with or without dysplasia (additional abnormality of the cells). Ablation (heating to the point of injury and removal) of Barrett’s esophagus is one method for reversing this disease. The HALO devices are endoscopic tools used to ablate Barrett’s esophagus.Open
    Principal Investigator:
    Roy Soetikno, MD

    Contact:
    Interventional Endoscopy Services
    415-600-1151    		Comparison of Linear Array Endoscopic Ultrasonography (transduodenal, transgastric and combination) and Multidetector Computed Tomography for the Preoperative Evaluation of Pancreatic Cancer. Subjects undergoing Endoscopic evaluation of the pancreas due to suspected or diagnosed pancreatic cancer or mass (tumor)Open
    Principal Investigator:
    William Snape, MD

    Contact:
    Mary Greene
    415-600-1367
    Email greenem@cpmcri.org    		A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP 102 for the Treatment of Symptomatic Gastroparesis in Patients With Diabetes Mellitus
    Visit the Diabetes Mellitus study on ClinicalTrials.gov.    		Subject is 18 to 80 years of age; Type 1 or type 2 diabetes mellitus and diagnosis with gastroparesisOpen


    Back to top

    Pancreatic Cancer

    CPMC Research Institute Pancreatic Cancer Clinical Trials


    updated 4/1/2010

    Back to top